This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy International Europe

Savings Deadline Expires In:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
2-4 December 2024
Convention Centre DublinDublin, Ireland

Jordan Schecter
VP, Multiple Myeloma at Johnson & Johnson
Speaker

Profile

Jordan M Schecter, MD is currently the Vice President for the Multiple Myeloma Disease Area Stronghold at Johnson & Johnson; Research and Development. In this role, he is responsible for the end-to-end Multiple Myeloma strategy from early discovery, translational research, early development, late development, and post-commercialization strategy. Prior to assuming this role in January 2024, he was the global clinical leader for Ciltacabtagene Autoleucel (CARVYKTI ®) an approved CAR-T therapy for Relapsed Multiple Myeloma).

Previous to this role, Dr. Schecter was the co-Clinical lead for Daratumumab (Darzalex ®), a monoclonal antibody first approved in 2015 for the treatment of Multiple Myeloma. Prior to joining Janssen, Dr. Schecter was an associate professor of medicine at Columbia University Medical Center in New York City where he was involved in clinical research for Multiple Myeloma and AL Amyloidosis. He earned his M.D. at Warren Alpert Medical School and completed his internship at Rhode Island Hospital, both at Brown University, and completed his residency and a fellowship in medical hematology and oncology at Columbia University Medical Center in New York City.

Agenda Sessions

  • Cilta-cel: The Story of a llama-inspired, autologous CAR-T product for Multiple Myeloma

    09:00